Cytokinetics Inc (CYTK)

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Ticker: CYTK
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $7.47B
52-week range: $53.55 - $88.31

Valuation

Share price: $53.69 (close of Nov 6, 2026)
P/E (TTM): -8.87x
Price to book: -23.24x
Price to free cash flow: -12.68x
Enterprise value: $7.14B
Book value per share: $-2.31

Price performance

Period	Change
1 day	-3.35%
5 days	-14.76%
1 month	-12.49%
3 months	-34.02%
6 months	-28.26%
Year to date	-15.50%
1 year	-10.96%
3 years	+55.94%
5 years	+30.63%
10 years	+468.15%
All time	-44.97%

Short interest

As of: Oct 15, 2026
Short % of float: 20.46%
Shares short: 18.63M
Days to cover: 8.71
Change since prior report: -3.65%
Source: FINRA consolidated short interest

Profitability and growth

Return on invested capital: -98.02%
Return on assets: -55.10%
Return on capital employed: -50.10%
Net margin: -891.60%
EBITDA margin: -683.94%

Cash flow and balance sheet

Free cash flow yield (TTM): -7.88%
Current ratio: 3.36x
Net debt to EBITDA: 0.52x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
Revenue: $88.04M
EBITDA: -$602.13M
Net income: -$784.96M
Earnings per share: $-6.54
Research and development: $416.03M
Interest expense: $45.58M
Shares outstanding: 120.10M

Income statement by year

Period end	Revenue	Net income	EPS
2025-12-31	$88.04M	-$784.96M	-$6.54
2024-12-31	$18.47M	-$589.53M	-$5.26
2023-12-31	$7.53M	-$526.24M	-$5.45
2022-12-31	$94.59M	-$388.95M	-$4.33
2021-12-31	$70.43M	-$215.31M	-$2.80
2020-12-31	$55.83M	-$127.29M	-$1.97
2019-12-31	$26.87M	-$121.69M	-$2.11
2018-12-31	$31.50M	-$106.29M	-$1.95
2017-12-31	$13.37M	-$127.79M	-$2.59
2016-12-31	$106.41M	$16.45M	$0.41

Margins and returns by year

Period end	Net margin	Return on equity	Return on capital
2025-12-31	-891.60%	-	-98.02%
2024-12-31	-3,191.11%	-	-82.08%
2023-12-31	-6,988.63%	-	-134.31%
2022-12-31	-411.21%	-	-50.47%
2021-12-31	-305.72%	-88.29%	-44.40%
2020-12-31	-228.00%	-112.27%	-57.70%
2019-12-31	-452.93%	-	-241.58%
2018-12-31	-337.41%	-	-128.64%
2017-12-31	-955.94%	-116.34%	-80.07%
2016-12-31	15.46%	17.44%	15.04%

Cash and debt by year

Period end	Cash	Debt
2025-12-31	$1.20B	$246.38M
2024-12-31	$1.22B	$93.23M
2023-12-31	$655.40M	$58.38M
2022-12-31	$829.30M	$63.81M
2021-12-31	$623.70M	$47.37M
2020-12-31	$501.00M	$46.21M
2019-12-31	$267.80M	$45.05M
2018-12-31	$198.70M	$39.81M
2017-12-31	$285.40M	$31.78M
2016-12-31	$163.90M	$27.38M

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	-$534.82M	$112.29M
2024-12-31	-$399.80M	$97.84M
2023-12-31	-$415.75M	$72.06M
2022-12-31	-$310.85M	$47.85M
2021-12-31	-$191.39M	$26.83M
2020-12-31	-$2.11M	$17.62M
2019-12-31	-$93.53M	$10.76M
2018-12-31	-$102.10M	$9.76M
2017-12-31	-$104.64M	$9.03M
2016-12-31	$35.39M	$7.15M

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-04	Sep 2026	-$1.50
2026-08-06	Jun 2026	-$1.63
2026-05-05	Mar 2026	-$1.67
2026-02-24	Dec 2025	-$1.48
2025-11-05	Sep 2025	-$1.59
2025-08-07	Jun 2025	-$1.34
2025-05-06	Mar 2025	-$1.41
2025-02-27	Dec 2024	-$1.22

Filings and sources

Company website: cytokinetics.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades